6
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Structural definition of a pan-sarbecovirus neutralizing epitope on the spike S2 subunit

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Three betacoronaviruses have crossed the species barrier and established human-to-human transmission causing significant morbidity and mortality in the past 20 years. The most current and widespread of these is SARS-CoV-2. The identification of CoVs with zoonotic potential in animal reservoirs suggests that additional outbreaks could occur. Monoclonal antibodies targeting conserved neutralizing epitopes on diverse CoVs can form the basis for prophylaxis and therapeutic treatments and enable the design of vaccines aimed at providing pan-CoV protection. We previously identified a neutralizing monoclonal antibody, CV3-25 that binds to the SARS-CoV-2 spike, neutralizes the SARS-CoV-2 Beta variant comparably to the ancestral Wuhan Hu-1 strain, cross neutralizes SARS-CoV-1 and binds to recombinant proteins derived from the spike-ectodomains of HCoV-OC43 and HCoV-HKU1. Here, we show that the neutralizing activity of CV3-25 is maintained against the Alpha, Delta, Gamma and Omicron variants of concern as well as a SARS-CoV-like bat coronavirus with zoonotic potential by binding to a conserved linear peptide in the stem-helix region. Negative stain electron microscopy and a 1.74 Å crystal structure of a CV3-25/peptide complex demonstrates that CV3-25 binds to the base of the stem helix at the HR2 boundary to an epitope that is distinct from other stem-helix directed neutralizing mAbs.

          Abstract

          Structural and functional characterisation of an antibody CV3-25 reveals wide neutralisation spectrum of the antibody against multiple SARS-CoV2 variants.

          Related collections

          Most cited references73

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          A pneumonia outbreak associated with a new coronavirus of probable bat origin

          Since the outbreak of severe acute respiratory syndrome (SARS) 18 years ago, a large number of SARS-related coronaviruses (SARSr-CoVs) have been discovered in their natural reservoir host, bats 1–4 . Previous studies have shown that some bat SARSr-CoVs have the potential to infect humans 5–7 . Here we report the identification and characterization of a new coronavirus (2019-nCoV), which caused an epidemic of acute respiratory syndrome in humans in Wuhan, China. The epidemic, which started on 12 December 2019, had caused 2,794 laboratory-confirmed infections including 80 deaths by 26 January 2020. Full-length genome sequences were obtained from five patients at an early stage of the outbreak. The sequences are almost identical and share 79.6% sequence identity to SARS-CoV. Furthermore, we show that 2019-nCoV is 96% identical at the whole-genome level to a bat coronavirus. Pairwise protein sequence analysis of seven conserved non-structural proteins domains show that this virus belongs to the species of SARSr-CoV. In addition, 2019-nCoV virus isolated from the bronchoalveolar lavage fluid of a critically ill patient could be neutralized by sera from several patients. Notably, we confirmed that 2019-nCoV uses the same cell entry receptor—angiotensin converting enzyme II (ACE2)—as SARS-CoV.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

            Summary The recent emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) in China and its rapid national and international spread pose a global health emergency. Cell entry of coronaviruses depends on binding of the viral spike (S) proteins to cellular receptors and on S protein priming by host cell proteases. Unravelling which cellular factors are used by SARS-CoV-2 for entry might provide insights into viral transmission and reveal therapeutic targets. Here, we demonstrate that SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming. A TMPRSS2 inhibitor approved for clinical use blocked entry and might constitute a treatment option. Finally, we show that the sera from convalescent SARS patients cross-neutralized SARS-2-S-driven entry. Our results reveal important commonalities between SARS-CoV-2 and SARS-CoV infection and identify a potential target for antiviral intervention.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              UCSF Chimera--a visualization system for exploratory research and analysis.

              The design, implementation, and capabilities of an extensible visualization system, UCSF Chimera, are discussed. Chimera is segmented into a core that provides basic services and visualization, and extensions that provide most higher level functionality. This architecture ensures that the extension mechanism satisfies the demands of outside developers who wish to incorporate new features. Two unusual extensions are presented: Multiscale, which adds the ability to visualize large-scale molecular assemblies such as viral coats, and Collaboratory, which allows researchers to share a Chimera session interactively despite being at separate locales. Other extensions include Multalign Viewer, for showing multiple sequence alignments and associated structures; ViewDock, for screening docked ligand orientations; Movie, for replaying molecular dynamics trajectories; and Volume Viewer, for display and analysis of volumetric data. A discussion of the usage of Chimera in real-world situations is given, along with anticipated future directions. Chimera includes full user documentation, is free to academic and nonprofit users, and is available for Microsoft Windows, Linux, Apple Mac OS X, SGI IRIX, and HP Tru64 Unix from http://www.cgl.ucsf.edu/chimera/. Copyright 2004 Wiley Periodicals, Inc.
                Bookmark

                Author and article information

                Contributors
                lstamata@fredhutch.org
                mpancera@fredhutch.org
                amcguire@fredhutch.org
                Journal
                Commun Biol
                Commun Biol
                Communications Biology
                Nature Publishing Group UK (London )
                2399-3642
                11 April 2022
                11 April 2022
                2022
                : 5
                : 342
                Affiliations
                [1 ]GRID grid.270240.3, ISNI 0000 0001 2180 1622, Fred Hutchinson Cancer Research Center, , Vaccine and Infectious Disease Division, ; Seattle, WA USA
                [2 ]GRID grid.214007.0, ISNI 0000000122199231, Department of Integrative Structural and Computational Biology, , The Scripps Research Institute, ; La Jolla, CA USA
                [3 ]GRID grid.214007.0, ISNI 0000000122199231, Department of Immunology and Microbiology, , The Scripps Research Institute, ; La Jolla, CA USA
                [4 ]GRID grid.116068.8, ISNI 0000 0001 2341 2786, Ragon Institute of MGH, , MIT and Harvard, ; Cambridge, MA USA
                [5 ]GRID grid.34477.33, ISNI 0000000122986657, Department of Global Health, , University of Washington, ; Seattle, WA USA
                [6 ]GRID grid.94365.3d, ISNI 0000 0001 2297 5165, Vaccine Research Center, , NAID, NIH, ; Bethesda, MD USA
                [7 ]GRID grid.34477.33, ISNI 0000000122986657, Department of Laboratory Medicine and Pathology, , University of Washington, ; Seattle, WA USA
                Author information
                http://orcid.org/0000-0001-9891-916X
                http://orcid.org/0000-0001-8421-6519
                http://orcid.org/0000-0001-6440-7019
                http://orcid.org/0000-0001-5858-2662
                http://orcid.org/0000-0003-0498-9162
                http://orcid.org/0000-0001-9749-9431
                http://orcid.org/0000-0001-5740-4303
                http://orcid.org/0000-0001-6711-9864
                http://orcid.org/0000-0001-8837-7520
                http://orcid.org/0000-0002-9695-8138
                http://orcid.org/0000-0001-7153-3769
                http://orcid.org/0000-0002-1106-7097
                http://orcid.org/0000-0001-9217-6270
                http://orcid.org/0000-0003-1841-6859
                Article
                3262
                10.1038/s42003-022-03262-7
                9001700
                35411021
                9383beef-f5e2-4c54-8928-7912e524809e
                © The Author(s) 2022

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 10 January 2022
                : 11 March 2022
                Funding
                Funded by: Fast Grants (part of Emergent Ventures at George Mason University)
                Funded by: Fred Hutch COVID-19 Research Fund
                Funded by: M.J. Murdock Charitable Trust
                Categories
                Article
                Custom metadata
                © The Author(s) 2022

                electron microscopy,x-ray crystallography,viral infection

                Comments

                Comment on this article